PRNewsWire
25 Mar 2026, 13:00 UTC · 33w ago
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky
Impact · against what's priced in
Soleno Therapeutics faces significant valuation risk as a class action lawsuit alleges the clinical data supporting its sole commercial product, VYKAT XR, was fraudulent and safety risks were concealed. For Limbach Holdings and AdaptHealth, the news confirms existing negative sentiment following guidance cuts.
- SLNO−0.90
No priced-in read yet





